JP2005533825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533825A5 JP2005533825A5 JP2004518103A JP2004518103A JP2005533825A5 JP 2005533825 A5 JP2005533825 A5 JP 2005533825A5 JP 2004518103 A JP2004518103 A JP 2004518103A JP 2004518103 A JP2004518103 A JP 2004518103A JP 2005533825 A5 JP2005533825 A5 JP 2005533825A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- halo
- compound
- compound according
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000005843 halogen group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 6
- 210000004351 coronary vessel Anatomy 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- 230000006907 apoptotic process Effects 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- -1 trifluorophenoxy Chemical group 0.000 claims 4
- 208000020084 Bone disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 206010019773 Hepatitis G Diseases 0.000 claims 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000027747 Kennedy disease Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 231100000360 alopecia Toxicity 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 208000001848 dysentery Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100039898 Interleukin-18 Human genes 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010043781 Thyroiditis chronic Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000005000 autoimmune gastritis Diseases 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 210000001187 pylorus Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 125000004360 trifluorophenyl group Chemical group 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39259202P | 2002-06-28 | 2002-06-28 | |
| US43507302P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/020557 WO2004002961A1 (en) | 2002-06-28 | 2003-06-27 | Caspase inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010023632A Division JP2010143942A (ja) | 2002-06-28 | 2010-02-04 | カスパーゼインヒビターおよびそれらの用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533825A JP2005533825A (ja) | 2005-11-10 |
| JP2005533825A5 true JP2005533825A5 (enExample) | 2006-08-03 |
| JP4616643B2 JP4616643B2 (ja) | 2011-01-19 |
Family
ID=30003264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004518103A Expired - Fee Related JP4616643B2 (ja) | 2002-06-28 | 2003-06-27 | カスパーゼインヒビターおよびそれらの用途 |
| JP2010023632A Pending JP2010143942A (ja) | 2002-06-28 | 2010-02-04 | カスパーゼインヒビターおよびそれらの用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010023632A Pending JP2010143942A (ja) | 2002-06-28 | 2010-02-04 | カスパーゼインヒビターおよびそれらの用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7553852B2 (enExample) |
| EP (1) | EP1539701A1 (enExample) |
| JP (2) | JP4616643B2 (enExample) |
| KR (1) | KR20050013260A (enExample) |
| CN (1) | CN100503572C (enExample) |
| AR (1) | AR040350A1 (enExample) |
| AU (1) | AU2003248758A1 (enExample) |
| BR (1) | BR0312232A (enExample) |
| CA (1) | CA2493646A1 (enExample) |
| IL (1) | IL165986A0 (enExample) |
| MX (1) | MXPA05000069A (enExample) |
| NO (1) | NO20050851L (enExample) |
| NZ (1) | NZ537807A (enExample) |
| PE (1) | PE20040728A1 (enExample) |
| PL (1) | PL374598A1 (enExample) |
| RU (1) | RU2005102094A (enExample) |
| TW (1) | TW200404783A (enExample) |
| UY (1) | UY27872A1 (enExample) |
| WO (1) | WO2004002961A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
| BR0312232A (pt) | 2002-06-28 | 2005-05-10 | Vertex Pharma | Inibidores de caspases e seus usos |
| JP4675628B2 (ja) * | 2002-12-20 | 2011-04-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | ４−オキソ−３−（１−オキソ−１ｈ−イソキノリン−２−イルアセチルアミノ）−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用 |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| CA2559303C (en) | 2004-03-12 | 2013-09-10 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
| CN102362867A (zh) | 2004-05-15 | 2012-02-29 | 沃泰克斯药物股份有限公司 | 使用ice抑制剂治疗癫痫发作 |
| EP1778221A2 (en) | 2004-05-27 | 2007-05-02 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
| CA2569763C (en) | 2004-06-08 | 2013-03-12 | Decode Chemistry, Inc. | 2,4-diaminoquinazolines for spinal muscular atrophy |
| AU2005272627A1 (en) * | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| EP1796660B1 (en) | 2004-09-17 | 2016-11-23 | BioMAS Ltd. | Use of ammonium trichloro(dioxyethylene-o,o')tellurate (as101) for the inhibition of interleukin-1beta-converting enzyme |
| CN101098855B (zh) * | 2004-11-24 | 2012-06-06 | 沃泰克斯药物股份有限公司 | 3-[2-(3-酰氨基-2-氧代-2h-吡啶-1-基)-乙酰氨基]-4-氧代-戊酸衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途 |
| CA2593005A1 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof |
| EP1898940A4 (en) * | 2005-06-07 | 2010-05-26 | Univ Pennsylvania | Alpha2beta1 / GPIa IIA INTEGRIN INHIBITORS |
| US8987306B2 (en) * | 2005-06-07 | 2015-03-24 | The Trustees Of The University Of Pennsylvania | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold |
| JP2009502922A (ja) * | 2005-07-28 | 2009-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼ阻害剤プロドラッグ |
| WO2007027742A2 (en) * | 2005-08-31 | 2007-03-08 | The Trustees Of The University Of Pennsylvania | SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS |
| WO2008016973A1 (en) | 2006-08-01 | 2008-02-07 | Families Of Spinal Muscular Atrophy | 2,4-diaminoquinazolines for spinal muscular atrophy |
| ATE523493T1 (de) * | 2006-09-11 | 2011-09-15 | Organon Nv | 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate |
| WO2008073388A2 (en) * | 2006-12-11 | 2008-06-19 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making and methods of use |
| US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
| FR2923160B1 (fr) | 2007-11-02 | 2013-07-26 | Pasteur Institut | Composes destines a prevenir ou traiter une infection virale. |
| EP2635906A4 (en) | 2010-11-05 | 2014-04-02 | Univ Brandeis | Ice inhibiting compounds and uses thereof |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| CA2862084C (en) | 2012-01-26 | 2021-05-11 | Ptc Therapeutics, Inc. | 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy |
| WO2015175381A1 (en) | 2014-05-12 | 2015-11-19 | Conatus Pharmaceuticals, Inc. | Treatment of the complications of chronic liver disease with caspase inhibitors |
| WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
| JP2019500397A (ja) | 2015-12-31 | 2019-01-10 | クオナトウス ファーマシューティカルズ，インコーポレイテッド | カスパーゼ阻害剤を肝疾患の治療に使用する方法 |
| RU2019113150A (ru) | 2016-10-05 | 2020-11-06 | Новартис Аг | Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения |
| EP3935042B1 (en) * | 2019-03-07 | 2024-08-28 | NOBO Medicine Inc. | Caspase inhibitors and methods of use thereof |
| WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
| KR102670554B1 (ko) * | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| DD232699A1 (de) * | 1983-11-18 | 1986-02-05 | Adw Ddr | Verfahren zur herstellung von chinazolin-4-on-3-alkansaeuren und deren estern |
| FR2582514B1 (fr) * | 1985-05-30 | 1988-02-19 | Rhone Poulenc Sante | Medicaments a base d'amides, nouveaux amides et leur preparation |
| US5714484A (en) | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6420522B1 (en) * | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
| US6063794A (en) * | 1996-10-11 | 2000-05-16 | Cor Therapeutics Inc. | Selective factor Xa inhibitors |
| AU738341B2 (en) | 1996-10-11 | 2001-09-13 | Abbott Gmbh & Co. Kg | Asparate ester inhibitors of interleukin-1beta converting enzyme |
| KR20000049047A (ko) | 1996-10-11 | 2000-07-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 술폰아미드 인터루킨-1β 전환 효소 억제제 |
| WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| ES2296625T3 (es) | 1999-05-07 | 2008-05-01 | Encysive Pharmaceuticals, Inc | Derivados del acido carboxilico que inhiben el enlace de las integrinas con sus receptores. |
| SI20876B (sl) | 1999-05-07 | 2009-08-31 | Texas Biotechnology Corp | Derivati propanojske kisline, ki inhibirajo vezavo integrinov na njihove receptorje |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| EP1289993B9 (en) | 2000-06-07 | 2008-08-20 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| AU2002348533A1 (en) * | 2001-10-09 | 2003-05-26 | Vertex Pharmaceuticals Incorporated | Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof |
| AU2003211052A1 (en) * | 2002-02-11 | 2003-09-04 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| AU2003225088A1 (en) | 2002-04-19 | 2003-11-03 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
| BR0312232A (pt) | 2002-06-28 | 2005-05-10 | Vertex Pharma | Inibidores de caspases e seus usos |
| JP4675628B2 (ja) | 2002-12-20 | 2011-04-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | ４−オキソ−３−（１−オキソ−１ｈ−イソキノリン−２−イルアセチルアミノ）−ペンタン酸のエステル誘導体およびアミド誘導体、ならびにカスパーゼインヒビターとしてのそれらの使用 |
| PE20050159A1 (es) * | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| CN101098855B (zh) | 2004-11-24 | 2012-06-06 | 沃泰克斯药物股份有限公司 | 3-[2-(3-酰氨基-2-氧代-2h-吡啶-1-基)-乙酰氨基]-4-氧代-戊酸衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途 |
-
2003
- 2003-06-27 BR BR0312232-8A patent/BR0312232A/pt not_active IP Right Cessation
- 2003-06-27 RU RU2005102094/04A patent/RU2005102094A/ru unknown
- 2003-06-27 NZ NZ537807A patent/NZ537807A/en unknown
- 2003-06-27 KR KR10-2004-7021300A patent/KR20050013260A/ko not_active Ceased
- 2003-06-27 AU AU2003248758A patent/AU2003248758A1/en not_active Abandoned
- 2003-06-27 PE PE2003000653A patent/PE20040728A1/es not_active Application Discontinuation
- 2003-06-27 US US10/609,147 patent/US7553852B2/en not_active Expired - Fee Related
- 2003-06-27 TW TW092117681A patent/TW200404783A/zh unknown
- 2003-06-27 AR ARP030102352A patent/AR040350A1/es unknown
- 2003-06-27 EP EP03762231A patent/EP1539701A1/en not_active Withdrawn
- 2003-06-27 JP JP2004518103A patent/JP4616643B2/ja not_active Expired - Fee Related
- 2003-06-27 CA CA002493646A patent/CA2493646A1/en not_active Abandoned
- 2003-06-27 MX MXPA05000069A patent/MXPA05000069A/es unknown
- 2003-06-27 IL IL16598603A patent/IL165986A0/xx unknown
- 2003-06-27 PL PL03374598A patent/PL374598A1/xx not_active Application Discontinuation
- 2003-06-27 WO PCT/US2003/020557 patent/WO2004002961A1/en not_active Ceased
- 2003-06-27 CN CNB038187930A patent/CN100503572C/zh not_active Expired - Fee Related
- 2003-06-30 UY UY27872A patent/UY27872A1/es unknown
-
2005
- 2005-02-17 NO NO20050851A patent/NO20050851L/no not_active Application Discontinuation
-
2009
- 2009-05-12 US US12/464,380 patent/US8129381B2/en not_active Expired - Fee Related
-
2010
- 2010-02-04 JP JP2010023632A patent/JP2010143942A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533825A5 (enExample) | ||
| JP2003535865A5 (enExample) | ||
| JP2006513220A5 (enExample) | ||
| RU2005102094A (ru) | Ингибиторы каспазы и их применение | |
| JP2003534325A5 (enExample) | ||
| RU2005140657A (ru) | Ингибиторы каспаз и их применение | |
| JP2003506389A5 (enExample) | ||
| JP2007525503A5 (enExample) | ||
| JP2002514649A (ja) | エポチロン誘導体、それらの製造方法、並びにそれらの使用 | |
| JP2010523647A (ja) | 安定した無水結晶形ドセタキセル及びその製造方法 | |
| KR20200120177A (ko) | 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1h-피롤-3-일]-n-메틸메탄아민의 신규염, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
| DE69128477T2 (de) | Benzopyranderivat | |
| JP2009502922A5 (enExample) | ||
| MXPA04002653A (es) | Metodo para preparar compuestos de pirimidinona y sales farmaceuticamente aceptables del mismo. | |
| RU2007123615A (ru) | Производные 3-[2-(3-ациламино-2-оксо-2н-пиридин-1-ил)-ацетиламино]-4-оксо-пентановой кислоты и их применение в качестве ингибиторов каспазы | |
| RU2006134258A (ru) | Ингибиторы каспаз и их применение | |
| JPH03193799A (ja) | ３―（ｌ―ピログルタミル）―ｌ―チアゾリジン―４―カルボン酸およびその誘導体の製造方法 | |
| US7638634B2 (en) | Amorphous esomeprazole hydrate | |
| CN101939289A (zh) | 用于制备伏立诺他的新方法 | |
| JP3652713B2 (ja) | 粒径の改善されたスピログリコールの製造方法 | |
| WO2016075588A1 (en) | Stable amorphous daclatasvir dihydrochloride | |
| CA2551501A1 (en) | Tolterodine, compositions and uses thereof, and preparation of the same | |
| CA2451979A1 (en) | Novel modifications of the trometamol salt of r-thioctic acid and method for producing the same | |
| CN100509788C (zh) | 神经降压素活性的2,3-二芳基-吡唑烷衍生物 | |
| KR101012135B1 (ko) | 발사르탄 메틸 에스테르의 제조방법 |